Skip to main content
. 2018 Jan 19;26(6):2031–2038. doi: 10.1007/s00520-017-4035-7

Table 2.

Baseline demographic and clinical characteristics

Characteristic Total patients enrolled in the study N = 154 Patients who received a PRBC transfusion N = 147
Sex, n (%)
 Female 107 (69.5) 100 (68.0)
 Male 47 (30.5) 47 (32.0)
Age, mean (SD), years 65.3 (9.8) 65.3 (9.9)
  < 65 years, n (%) 70 (45.5) 66 (44.9)
  ≥ 65 years, n (%) 84 (54.5) 81 (55.1)
Primary tumor type, n (%)
 Gynecological cancer 43 (27.9) 38 (25.9)
 Non-small cell lung cancer 32 (20.8) 32 (21.8)
 Small cell lung cancer 25 (16.2) 24 (16.3)
 Gastrointestinal cancer 19 (12.3) 18 (12.2)
 Breast cancer 14 (9.1) 14 (9.5)
 Urogenital cancer 7 (4.5) 7 (4.8)
 Hematological malignancies 7 (4.5) 7 (4.8)
 Othera 7 (4.5) 7 (4.8)
Chemotherapy type, n (%)
 Platinum 113 (73.4) 107 (72.8)
 Non-platinum 41 (26.6) 40 (27.2)
Chemotherapy line, n (%)
 First 100 (64.9) 95 (64.6)
 Second 54 (35.1) 52 (35.4)
Signs and symptoms of anemia, n (%)
 Yes 137 (89.0) 133 (90.5)
 No 17 (11.0) 14 (9.5)
Comorbidities relevant to the anemia, n (%)
 Yes 41 (27.9)
  Chronic pulmonary disease 22 (15.0)
  Congestive heart failure or coronary heart disease 9 (6.1)
  Cerebral vascular disease 2 (1.4)
  Otherb 17 (11.6)
 No 106 (72.1)

PRBC packed red blood cell, SD standard deviation

aIncludes bone/sarcoma, brain, head and neck, skin, thyroid cancers, or missing

bNot specified